# A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

> **NCT07298330** · PHASE3 · RECRUITING · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Hepatitis D Infection

## Interventions

- **DRUG:** Brelovitug 300 mg
- **DRUG:** Brelovitug 900 mg
- **DRUG:** Delayed Treatment with Brelovitug 300mg

## Key facts

- **NCT ID:** NCT07298330
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2026-08
- **Final completion:** 2029-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298330, "A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07298330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*